Medical Industry Feature

Host: Jennifer Caudle, DO Guest: Ravi Jhaveri, MD Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza burden, Dr. Jennifer Caudle speaks with Dr. Ravi Jhaveri, Division Head of Pediatric Infectious Diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago. Reference:1. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden averted by vaccination. https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html. Accessed April 8, 2022. USA-FCV-24-0051 08/24